India, March 31 -- Galapagos (GLPG,GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity interests of Ouro Medicines, a privately held biotechnology company. Under the Framework Agreement, Galapagos' share of the total consideration for the acquisition amounts to 50% of the upfront consideration of $1.675 billion and 50% of any contingent milestone payments, which also includes the consideration under the asset acquisition term sheet. The Framework Agreement with Gilead comprises relief under the Option, License and Collaboration Agreement dated July 14, 2019 between Galapagos and Gilead, to enable Galapagos to deploy at least $500 million of ...